CLINICAL IMPACT OF DOSE MODIFICATION AND DOSE INTENSITY ON RESPONSE TO PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIAS

被引：0

作者：

Nicolini, F. E. ^{[1
]}

Cortes, J. E. ^{[2
]}

Kim, D. W. ^{[3
]}

Pinilla-Ibarz, J. ^{[4
]}

le Coutre, P. D. ^{[5
]}

Paquette, R. ^{[6
]}

Chuah, C. ^{[7
]}

Apperley, J. F. ^{[8
]}

Khoury, H. J. ^{[9
]}

Talpaz, M. ^{[10
]}

DiPersio, J. F. ^{[11
]}

DeAngelo, D. J. ^{[12
]}

Abruzzese, E. ^{[13
]}

Rea, D. ^{[14
,15
]}

Baccarani, M. ^{[16
]}

Muller, M. C. ^{[17
]}

Gambacorti-Passerini, C. ^{[18
]}

Lustgarten, S. ^{[19
]}

Rivera, V. M. ^{[19
]}

Haluska, F. G. ^{[19
]}

Guilhot, F. ^{[20
]}

Deininger, M. W. ^{[21
]}

Hughes, T. P. ^{[22
]}

Shah, N. P. ^{[23
]}

Kantarjian, H. M. ^{[2
]}

Hochhaus, A. ^{[24
]}

机构：

[1] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[5] Charite, D-13353 Berlin, Germany

[6] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA

[7] Singapore Gen Hosp, Duke NUS Grad Med Sch, Singapore, Singapore

[8] Univ London Imperial Coll Sci Technol & Med, London, England

[9] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[10] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[11] Washington Univ, Sch Med, St Louis, MO USA

[12] Dana Farber Canc Inst, Boston, MA 02115 USA

[13] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy

[14] Hop St Louis, Serv Malad Sang, Paris, France

[15] Hop St Louis, CIC Clin Invest Ctr, Paris, France

[16] S Orsola Malpighi Univ Hosp, Bologna, Italy

[17] Univ Med, Med Klin 3, Mannheim, Germany

[18] Azienda Osped San Gerardo Univ Milano Bicocca, Unita Ric Clin Ematol, Monza, Italy

[19] ARIAD Pharmaceut Inc, Cambridge, MA USA

[20] Univ Hosp, CHU Poitiers, Poitiers, France

[21] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[22] Inst Med & Vet Sci, Adelaide, SA 5000, Australia

[23] Univ Calif San Francisco, San Francisco, CA 94143 USA

[24] Univ Klinikum Jena, Jena, Germany

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P894

引用

页码：334 / 334

页数：1

共 50 条

[31] Immunophenotypic Comparison of Philadelphia Chromosome-Like to Philadelphia Chromosome-Positive (Ph plus ) B-Lymphoblastic Leukemia
Choi, Sarah M.
Shao, Lina
Boyer, Daniel
MODERN PATHOLOGY, 2018, 31 : 507 - 508
[32] Safety and durability of ponatinib in patients with Philadelphia chromosome-positive (Ph plus ) leukemia: Long-term follow-up of an ongoing phase I study
Mauro, Michael J.
Cortes, Jorge E.
Kantarjian, Hagop M.
Shah, Neil P.
Bixby, Dale
Flinn, Ian
O'Hare, Thomas
Hu, Simin
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Druker, Brian J.
Deininger, Michael W. N.
Talpaz, Moshe
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[33] Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib
Yuya Sasaki
Hagop M. Kantarjian
Nicholas J. Short
Feng Wang
Ken Furudate
Hidetaka Uryu
Rebecca Garris
Nitin Jain
Koji Sasaki
Farhad Ravandi
Marina Konopleva
Guillermo Garcia-Manero
Latasha Little
Curtis Gumbs
Li Zhao
P. Andrew Futreal
Koichi Takahashi
Elias Jabbour
Leukemia, 2022, 36 : 1253 - 1260
[34] Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL).
Sasaki, Koji
Kantarjian, Hagop M.
Ravandi, Farhad
Thomas, Deborah A.
Cortes, Jorge E.
Pemmaraju, Naveen
Kadia, Tapan M.
Short, Nicholas James
Issa, Ghayas C.
Garris, Rebecca S.
Jeanis, Vicky
Moore, H. Gal
Garcia-Manero, Guillermo
Borthakur, Gautam
Wierda, William G.
Gachimova, Evguenia
O'Brien, Susan Mary
Jabbour, Elias
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[35] Safety and Durability of Ponatinib in Patients With Philadelphia Chromosome-Positive (Ph plus ) Leukemia: Long-term Follow-up of an Ongoing Phase 1 Study
Mauro, Michael J.
Cortes, Jorge E.
Kantarjian, Hagop M.
Shah, Neil P.
Bixby, Dale
Flinn, Ian W.
O'Hare, Thomas
Hu, Simin
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Druker, Brian J.
Deininger, Michael W.
Talpaz, Moshe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S137 - S138
[36] SAFETY AND DURABILITY OF PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIA: LONG-TERM FOLLOW-UP OF AN ONGOING PHASE 1 STUDY
Mauro, M.
Cortes, J.
Kantarjian, H.
Shah, N.
Bixby, D.
Flinn, I.
O'Hare, T.
Hu, S.
Rivera, V.
Clackson, T.
Turner, C.
Haluska, F.
Druker, B.
Deininger, Mi
Talpaz, M.
HAEMATOLOGICA, 2013, 98 : 295 - 296
[37] A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
Matloub, Yousif
Gore, Lia
Loh, Mignon L.
Pui, Chin-Hon
Hanley, Michael J.
Lu, Vickie
Leonard, E. Jane
Granier, Muriel
Biondi, Andrea
Silverman, Lewis B.
BLOOD, 2020, 136
[38] Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib
Yuya Sasaki
Hagop M. Kantarjian
Nicholas J. Short
Feng Wang
Ken Furudate
Hidetaka Uryu
Rebecca Garris
Nitin Jain
Koji Sasaki
Farhad Ravandi
Marina Konopleva
Guillermo Garcia-Manero
Latasha Little
Curtis Gumbs
Li Zhao
P. Andrew Futreal
Koichi Takahashi
Elias Jabbour
Leukemia, 2022, 36 : 1448 - 1448
[39] Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Kota, Vamsi
Brummendorf, Tim H.
Gambacorti-Passerini, Carlo
Cortes, Jorge E.
Lipton, Jeffrey H.
Kantarjian, Hagop M.
Kim, Dong-Wook
An, Fiona
Leip, Eric
Crescenzo, Rocco J.
Woloj, Mabel
Shapiro, Mark
Khoury, H. Jean
BLOOD, 2016, 128 (22)
[40] Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
Maiti, Abhishek
Kantarjian, Hagop
Ravandi, Farhad
Short, Nicholas
Daver, Naval
Pemmaraju, Naveen
Thomas, Deborah
Yilmaz, Musa
Kadia, Tapan
Sasaki, Koji
Garris, Rebecca
Garcia-Manero, Guillermo
DiNardo, Courtney
Konopleva, Marina
Estrov, Zeev
Jain, Nitin
Weirda, William
Jeanis, Vicky
Cortes, Jorge
O'Brien, Susan
Jabbour, Elias
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S257 - S258

← 1 2 3 4 5 →